About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: VTVT
- Previous Close: $5.47
- 50 Day Moving Average: $5.44
- 200 Day Moving Average: $5.80
- 52-Week Range: $4.65 - $7.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.01
- P/E Growth: 0.00
- Market Cap: $53.02M
- Outstanding Shares: 9,693,000
- Beta: 0.99
- Net Margins: -1,882.12%
- Return on Assets: -21.15%
Companies Related to vTv Therapeutics:
- Current Ratio: 4.93%
- Quick Ratio: 4.93%
What is vTv Therapeutics' stock symbol?
vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
Where is vTv Therapeutics' stock going? Where will vTv Therapeutics' stock price be in 2017?
4 equities research analysts have issued 12-month price objectives for vTv Therapeutics' stock. Their predictions range from $13.00 to $24.00. On average, they anticipate vTv Therapeutics' stock price to reach $16.50 in the next year.
When will vTv Therapeutics announce their earnings?
vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about vTv Therapeutics stock?
Here are some recent quotes from research analysts about vTv Therapeutics stock:
According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (2/15/2017)
HC Wainwright analysts commented, "We are more enthusiastic about the two diabetes drugs that should be ripe for partnering upon success in Phase 2. TTP399 completed a successful Phase 2b in August and TTP273 should have Phase 2b data in December, the nearest term catalyst," analyst Corey Davis wrote in a note.Related Link: vTV Therapeutics Completes Enrollment For PHase 2 TTP273 TrialOn the other hand, although Azeliragon could be "one of the next wave of promising Alzheimer's drugs," the analyst is not expecting the stock to move near term on this drug given the history and lack of data until 2018.The upcoming catalysts include TTP273 Phase 2 data in diabetes and publication of Phase 2 results from TTP399 in diabetes, both expected in late 2016. Also, potential partnerships on one or both of the diabetes drugs could also boost the stock.On the partnering front, Davis said larger firms such as the following would make a good fit:AstraZeneca plc (ADR) (NYSE: AZN).Boehringer Ingelheim Corporation.Eli Lilly and Co (NYSE: LLY).GlaxoSmithKline plc (ADR) (NYSE: GSK).Johnson & Johnson (NYSE: JNJ).Merck & Co., Inc. (NYSE: MRK).Novartis AG (ADR) (NYSE: NVS).Novo Nordisk A/S (ADR) (NYSE: NVO).Sanofi SA (ADR) (NYSE: SNY).Takeda Pharmaceutical Co Ltd (ADR) (OTC: TKPYY).Meanwhile, the analyst sees a potential upside of 81 percent in vTv shares with a $13 target price."Our target of $13 would only be a $425 million market cap. With some of the recent deals for diabetes drugs, a standard upfront milestone payment alone could allow the stock to reach our target," (9/26/2016)
Who owns vTv Therapeutics stock?
vTv Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (9.83%), Alyeska Investment Group L.P. (2.20%), Piper Jaffray & Co (1.90%), Wall Street Associates (1.70%), State Street Corp (0.89%) and Renaissance Technologies LLC (0.63%). Company insiders that own vTv Therapeutics stock include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman.
Who sold vTv Therapeutics stock? Who is selling vTv Therapeutics stock?
vTv Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates and State Street Corp.
Who bought vTv Therapeutics stock? Who is buying vTv Therapeutics stock?
vTv Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P. and Renaissance Technologies LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman.
How do I buy vTv Therapeutics stock?
Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of vTv Therapeutics stock cost?
One share of vTv Therapeutics stock can currently be purchased for approximately $5.38.